1. Home
  2. CHRS vs RELL Comparison

CHRS vs RELL Comparison

Compare CHRS & RELL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • RELL
  • Stock Information
  • Founded
  • CHRS 2010
  • RELL 1947
  • Country
  • CHRS United States
  • RELL United States
  • Employees
  • CHRS N/A
  • RELL N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • RELL Electronic Components
  • Sector
  • CHRS Health Care
  • RELL Technology
  • Exchange
  • CHRS Nasdaq
  • RELL Nasdaq
  • Market Cap
  • CHRS 194.1M
  • RELL 169.6M
  • IPO Year
  • CHRS 2014
  • RELL N/A
  • Fundamental
  • Price
  • CHRS $1.70
  • RELL $10.84
  • Analyst Decision
  • CHRS Strong Buy
  • RELL
  • Analyst Count
  • CHRS 4
  • RELL 0
  • Target Price
  • CHRS $4.51
  • RELL N/A
  • AVG Volume (30 Days)
  • CHRS 1.0M
  • RELL 163.2K
  • Earning Date
  • CHRS 11-07-2025
  • RELL 10-08-2025
  • Dividend Yield
  • CHRS N/A
  • RELL 2.21%
  • EPS Growth
  • CHRS N/A
  • RELL N/A
  • EPS
  • CHRS 1.55
  • RELL 0.01
  • Revenue
  • CHRS $272,209,000.00
  • RELL $209,791,000.00
  • Revenue This Year
  • CHRS N/A
  • RELL $4.72
  • Revenue Next Year
  • CHRS $109.48
  • RELL $14.93
  • P/E Ratio
  • CHRS $3.38
  • RELL $889.91
  • Revenue Growth
  • CHRS 52.33
  • RELL 6.17
  • 52 Week Low
  • CHRS $0.66
  • RELL $7.57
  • 52 Week High
  • CHRS $2.43
  • RELL $15.51
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 54.43
  • RELL 52.72
  • Support Level
  • CHRS $1.64
  • RELL $10.59
  • Resistance Level
  • CHRS $1.81
  • RELL $11.18
  • Average True Range (ATR)
  • CHRS 0.10
  • RELL 0.55
  • MACD
  • CHRS -0.02
  • RELL -0.07
  • Stochastic Oscillator
  • CHRS 42.32
  • RELL 14.06

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About RELL Richardson Electronics Ltd.

Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.

Share on Social Networks: